Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Agache I, Beltran J, Akdis C et al Allergy Volume 75, Issue 5 May 2020 Pages 1023-1042 https://doi.org/10.1111/all.14221 Aim: To assess the efficacy and safety of the five biologicals approved Continue Reading →